NEW YORK (
) is trading at unusually high volume Thursday with 1.6 million shares changing hands. It is currently at four times its average daily volume and trading down 25 cents (-2.6%) at $9.36 as of 4:02 p.m. ET.
Protalix BioTherapeutics has a market cap of $769.9 million and is part of the
industry. Shares are down 3.7% year to date as of the close of trading on Wednesday.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system primarily in the United States.
TheStreet Ratings rates Protalix BioTherapeutics as sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. You can view the full
See all heavy volume stocks in our
or get investment ideas from our